{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:31:58Z","timestamp":1791243118140,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0070347"],"award-info":[{"award-number":["NNF21OC0070347"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC00671"],"award-info":[{"award-number":["NNF21OC00671"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18SA0034956"],"award-info":[{"award-number":["NNF18SA0034956"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["2020\\u2010117043"],"award-info":[{"award-number":["2020\\u2010117043"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["117043"],"award-info":[{"award-number":["117043"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007505","name":"Kirsten and Freddy Johansens Foundation","doi-asserted-by":"publisher","award":["2017\\u2010 112697"],"award-info":[{"award-number":["2017\\u2010 112697"]}],"id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","award":["9065-00181B"],"award-info":[{"award-number":["9065-00181B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116893","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:39:29Z","timestamp":1742733569000},"page":"116893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development of a long-acting unbiased GIP receptor agonist for studies of GIP\u2019s role in bone metabolism"],"prefix":"10.1016","volume":"236","author":[{"given":"Esther Karen","family":"Tordrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Gadgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Windel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke Smidt","family":"Gasbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-3254","authenticated-orcid":false,"given":"Mette Marie","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116893_b0005","first-page":"3575","article-title":"Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide","volume":"85","author":"Deacon","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0010","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of Incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2025.116893_b0015","doi-asserted-by":"crossref","first-page":"11050","DOI":"10.1074\/jbc.M601203200","article-title":"Prohormone Convertase 1\/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor","volume":"281","author":"Ugleholdt","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116893_b0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2025.116893_b0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsb\u00f8ll","year":"2003","journal-title":"Regul Pept"},{"key":"10.1016\/j.bcp.2025.116893_b0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2025.116893_b0035","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.116893_b0040","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0045","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0050","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2025.116893_b0055","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0060","first-page":"1","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"2023","author":"El","year":"2023","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.bcp.2025.116893_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP - A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.01.040","article-title":"Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors","volume":"150","author":"Gabe","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0075","article-title":"Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","author":"Gasbjerg","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells \u2013 A review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides (n.y.)"},{"key":"10.1016\/j.bcp.2025.116893_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170224","volume":"125","author":"Gabe","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2025.116893_b0090","author":"Jones","year":"2020","journal-title":"Genetic and Biased Agonist-Mediated Reductions in \u03b2-Arrestin Recruitment Prolong cAMP Signaling at Glucagon Family Receptors"},{"key":"10.1016\/j.bcp.2025.116893_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16040","article-title":"Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice","author":"Gabe","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0100","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2025.116893_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic b-cells and adipocytes","author":"Mcintosh","year":"2012","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.bcp.2025.116893_b0110","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","article-title":"Bone Remodeling","volume":"1092","author":"Hadjidakis","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bcp.2025.116893_b0120","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2025.116893_b0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fendo.2019.00075","article-title":"Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment","volume":"10","author":"Schiellerup","year":"2019","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.116893_b0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41574-024-01000-z","article-title":"Gut hormones and bone homeostasis: potential therapeutic implications","volume":"20","author":"Bouvard","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bcp.2025.116893_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.749607","article-title":"Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes","volume":"9","author":"Kizilkaya","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bcp.2025.116893_b0140","doi-asserted-by":"crossref","first-page":"E729","DOI":"10.1210\/jc.2013-3766","article-title":"A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk","volume":"99","author":"Torekov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0145","doi-asserted-by":"crossref","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115079","article-title":"GIP\u2019s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2","volume":"130","author":"Gasbjerg","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/joim.12586","article-title":"Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project","volume":"281","author":"Katsoulis","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.bcp.2025.116893_b0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of Osteoporosis: New Mechanistic Insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bcp.2025.116893_b0170","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2015.06.006","article-title":"The Pathophysiology and Treatment of Osteoporosis","volume":"37","author":"Drake","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.bcp.2025.116893_b0175","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/med.21504","article-title":"The underlying pathophysiology and therapeutic approaches for osteoporosis","volume":"38","author":"Awasthi","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2025.116893_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and Benefits of Bisphosphonate Therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bcp.2025.116893_b0185","first-page":"313","article-title":"GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats, ACS Pharmacol","author":"Van Der Velden","year":"2021","journal-title":"Transl. Sci"},{"key":"10.1016\/j.bcp.2025.116893_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0214s70","article-title":"Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonist-Induced Arrestin Recruitment to Modified and Unmodified G Protein-Coupled Receptors","volume":"70","author":"Donthamsetti","year":"2015","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0195","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/mol.117.108787","article-title":"A Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation","volume":"92","author":"Kenakin","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/pr.118.016790","article-title":"Biased Receptor Signaling in Drug Discovery","volume":"71","author":"Kenakin","year":"2019","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2025.116893_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114001","article-title":"Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors","volume":"177","author":"Yuliantie","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0210","first-page":"S1","article-title":"The Concise Guide to PHARMACOLOGY 2023\/24: Introduction and Other Protein Targets","volume":"180","author":"Alexander","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u201330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","article-title":"A review of lipidation in the development of advanced protein and peptide therapeutics","volume":"295","author":"Menacho-Melgar","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.116893_b0230","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2025.116893_b0235","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.12181","article-title":"A novel long-acting glucose-dependent insulinotropic peptide analogue: Enhanced efficacy in normal and diabetic rodents","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0245","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1074\/jbc.M708740200","article-title":"Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain","volume":"283","author":"Runge","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2025.116893_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.regpep.2012.12.012","article-title":"The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs","volume":"181","author":"Simonsen","year":"2013","journal-title":"Regul Pept"},{"issue":"Suppl 6","key":"10.1016\/j.bcp.2025.116893_b0255","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcpt.13289","article-title":"Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system","volume":"126","author":"Gabe","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2025.116893_b0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.regpep.2011.12.006","article-title":"Functional importance of GLP-1 receptor species and expression levels in cell lines","volume":"175","author":"Knudsen","year":"2012","journal-title":"Regul Pept"},{"key":"10.1016\/j.bcp.2025.116893_b0265","doi-asserted-by":"crossref","unstructured":"Lau J. Bloch P. Sch\u00e4 L. Pettersson I. Spetzler J. Kofoed J. Madsen K. Knudsen L.B. Mcguire J. Steensgaard B. Strauss M. Gram D.X. Knudsen S.M. Nielsen F.S. Thygesen P. Reedtz-Runge S. Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide J Med Chem 58 18 2015 7370 7380 10.1021\/acs.jmedchem.5b00726.","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"10.1016\/j.bcp.2025.116893_b0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.bcp.2025.116893_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.116893_b0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","author":"Jensen","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences 104"},{"key":"10.1016\/j.bcp.2025.116893_b0285","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2025.116893_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides (n.y.)"},{"key":"10.1016\/j.bcp.2025.116893_b0295","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm0509997","article-title":"GIP(Lys16PAL) and GIP(Lys37PAL): Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential","volume":"49","author":"Irwin","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2025.116893_b0300","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jez.a.312","article-title":"Major contributions of comparative endocrinology to the development and exploitation of the incretin concept","volume":"305","author":"Conlon","year":"2006","journal-title":"J Exp Zool A Comp Exp Biol"},{"key":"10.1016\/j.bcp.2025.116893_b0305","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116893_b0310","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2025.116893_b0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.mce.2014.10.025","article-title":"Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice","volume":"401","author":"Pathak","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2025.116893_b0320","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s00125-015-3653-1","article-title":"Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL\/KsJ db\/db mice","volume":"58","author":"Pathak","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2025.116893_b0325","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bph.15497","article-title":"The therapeutic potential of GLP-1 receptor biased agonism","volume":"179","author":"Jones","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.116893_b0330","first-page":"1","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"2024","author":"Kizilkaya","year":"2024","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.bcp.2025.116893_b0335","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.071202","article-title":"Impact of Glucose-Dependent Insulinotropic Peptide on Age-Induced Bone Loss","volume":"23","author":"Ding","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2025.116893_b0340","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bone.2005.06.021","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover","volume":"37","author":"Xie","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2025.116893_b0350","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116065","article-title":"Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study","volume":"152","author":"Skov-Jeppesen","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0360","article-title":"Advances in Animal Models for Studying Bone Fracture Healing","volume":"10","author":"Gao","year":"2023","journal-title":"Bioengineering (basel)"},{"key":"10.1016\/j.bcp.2025.116893_b0365","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1210\/endo.139.2.5751","article-title":"Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research","volume":"139","author":"Aerssens","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2025.116893_b0370","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2025.116893_b0375","first-page":"392","article-title":"Short-term Administration of Glucagon-like Peptide-2","volume":"37","author":"Haderslev","year":"2002","journal-title":"Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon, Scand J Gastroenterol"},{"key":"10.1016\/j.bcp.2025.116893_b0380","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/jbmr.4308","article-title":"The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism\u2014A Randomized Crossover Study","volume":"36","author":"Skov-Jeppesen","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2025.116893_b0385","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jbmr.4792","article-title":"Development of a First-in-Class Unimolecular Dual GIP\/GLP-2 Analogue, GL-0001, for the Treatment of Bone Fragility","volume":"38","author":"Gobron","year":"2023","journal-title":"J. Bone Miner. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:10:41Z","timestamp":1777392641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":77,"alternative-id":["S0006295225001558"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116893","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a long-acting unbiased GIP receptor agonist for studies of GIP\u2019s role in bone metabolism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116893"}}